Analytical Data
-
Gene name
EYA2
- Application
-
Alternative Names
EAB 1; EAB1; EYA 2; EYA transcriptional coactivator and phosphatase 2; EYA2; EYA2_HUMAN; eyes absent 2 homolog (Drosophila); Eyes absent homolog 2 (Drosophila); Eyes absent homolog 2; Translation of this uORF probably lowers the translation efficiency of EYA2
-
Species
Human
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O00167
-
Expression Region
1-514aa
-
Molecular Weight
72.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EYA2, a member of the Eyes Absent (EYA) protein family, plays a significant role in various developmental processes and cell signaling pathways. This group of proteins is known for its involvement in the regulation of gene expression and the formation of specific tissues and organs during embryonic development. EYA2 is particularly essential in the development of the eye, kidney, and other organs, acting as a transcriptional co-activator that interacts with other key regulatory proteins. Research has increasingly focused on EYA2 due to its potential implications in various diseases, including cancer and congenital disorders. The recombinant protein version of EYA2 has become a valuable tool for dissecting its functional roles in cellular mechanisms and for understanding the molecular underpinnings of its associated pathologies. By producing recombinant EYA2, researchers aim to investigate its biochemical properties, binding interactions, and regulatory functions in cellular environments. This study is crucial for elucidating the pathways through which EYA2 operates and could lead to developments in targeted therapeutic strategies for diseases linked to EYA2 dysregulation. Overall, the exploration of EYA2 recombinant protein embodies a promising frontier in developmental biology and medical research, providing insights that could pave the way for innovative treatments and interventions.
